Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.
Newsroom
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN DIEGO, CA., September 2, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”…
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option SAN DIEGO, CA., August 21, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE…
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering SAN DIEGO, CA., August 20, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a…
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55…
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma. SAN DIEGO, July 29, 2025…
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi”…
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds SAN DIEGO, July 9, 2025 — Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a…
Calidi Biotherapeutics Announces Shareholder Letter from CEO
Calidi Biotherapeutics Announces Shareholder Letter from CEO SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of…
Calidi Biotherapeutics Presents Systemic Oncolytic Platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting
Calidi Biotherapeutics Presents Systemic Oncolytic platform with CD55-Enhanced Expression and IL-15 Superagonist Payload at ASCO Annual Meeting San Diego, CA – June 2, 2025 — Calidi Biotherapeutics Inc. (NYSE American:…
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced…